Načítá se...
Novel Approaches to Treatment of “Double-Refractory” Multiple Myeloma
Multiple myeloma refractory to both proteasome inhibitors and immunomodulatory agents (IMiDs) has a poor prognosis. With the increasing use of these agents as part of initial therapy, and then in the maintenance setting until disease progression, such drug resistance is an emerging problem of great...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3762449/ https://ncbi.nlm.nih.gov/pubmed/23714530 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/EdBook_AM.2013.33.e302 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|